» Articles » PMID: 19608354

Predicting Adherence to Treatment for Methamphetamine Dependence from Neuropsychological and Drug Use Variables

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2009 Jul 18
PMID 19608354
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Although some individuals who abuse methamphetamine have considerable cognitive deficits, no prior studies have examined whether neurocognitive functioning is associated with outcome of treatment for methamphetamine dependence. In an outpatient clinical trial of bupropion combined with cognitive behavioral therapy and contingency management (Shoptaw, S., Heinzerling, K.G., Rotheram-Fuller, E., Steward, T., Wang, J., Swanson, A.N., De La Garza, R., Newton, T., Ling, W., 2008. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 96, 222-232.), 60 methamphetamine-dependent adults completed three tests of reaction time and working memory at baseline. Other variables that were collected at baseline included measures of drug use, mood/psychiatric functioning, employment, social context, legal status, and medical status. We evaluated the relative predictive value of all baseline measures for treatment outcome using Classification and Regression Trees (CART; Breiman, L., Friedman, J.H., Olshen, R.A., Stone, C.J., 1984. Classification and Regression Trees. Wadsworth, Belmont, CA.), a nonparametric statistical technique that produces easily interpretable decision rules for classifying subjects that are particularly useful in clinical settings. Outcome measures were whether or not a participant completed the trial and whether or not most urine tests showed abstinence from methamphetamine abuse. Urine-verified methamphetamine abuse at the beginning of the study was the strongest predictor of treatment outcome; two psychosocial measures (e.g., nicotine dependence and Global Assessment of Functioning) also offered some predictive value. A few reaction time and working memory variables were related to treatment outcome, but these cognitive measures did not significantly aid prediction after adjusting for methamphetamine usage at the beginning of the study. On the basis of these findings, we recommend that research groups seeking to identify new predictors of treatment outcome compare the predictors to methamphetamine usage variables to assure that unique predictive power is attained.

Citing Articles

Perirhinal to prefrontal circuit in methamphetamine induced recognition memory deficits.

Hopkins J, Goldsmith S, Wood S, Nelson K, Carter J, Freels D Neuropharmacology. 2023; 240:109711.

PMID: 37673333 PMC: 10591958. DOI: 10.1016/j.neuropharm.2023.109711.


Decision-making tendencies and voucher spending independently support abstinence within contingency management for methamphetamine use disorder.

Lake M, Krishnamurti T, Murtaugh K, van Nunen L, Stein D, Shoptaw S Exp Clin Psychopharmacol. 2022; 31(2):324-329.

PMID: 35482632 PMC: 10116516. DOI: 10.1037/pha0000574.


Dopamine dysfunction in stimulant use disorders: mechanistic comparisons and implications for treatment.

Kohno M, Dennis L, McCready H, Hoffman W Mol Psychiatry. 2021; 27(1):220-229.

PMID: 34117366 PMC: 8664889. DOI: 10.1038/s41380-021-01180-4.


Identifying Behavioral Phenotypes in Chronic Illness: Self-Management of COPD and Comorbid Hypertension.

Perez-Benzo G, Muellers K, Chen S, Liu B, Bagiella E, OConor R Patient Educ Couns. 2020; 104(3):627-633.

PMID: 32921518 PMC: 7914263. DOI: 10.1016/j.pec.2020.08.025.


Executive function moderates naltrexone effects on methamphetamine-induced craving and subjective responses.

Lim A, Grodin E, Green R, Venegas A, Meredith L, Courtney K Am J Drug Alcohol Abuse. 2020; 46(5):565-576.

PMID: 32343625 PMC: 7920534. DOI: 10.1080/00952990.2020.1741002.


References
1.
Gonzalez R, Rippeth J, Carey C, Heaton R, Moore D, Schweinsburg B . Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug Alcohol Depend. 2004; 76(2):181-90. DOI: 10.1016/j.drugalcdep.2004.04.014. View

2.
Hardy D, Hinkin C . Reaction time performance in adults with HIV/AIDS. J Clin Exp Neuropsychol. 2003; 24(7):912-29. DOI: 10.1076/jcen.24.7.912.8391. View

3.
Salo R, Nordahl T, Possin K, Leamon M, Gibson D, Galloway G . Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Res. 2002; 111(1):65-74. DOI: 10.1016/s0165-1781(02)00111-7. View

4.
Smith E, Jonides J, Koeppe R . Dissociating verbal and spatial working memory using PET. Cereb Cortex. 1996; 6(1):11-20. DOI: 10.1093/cercor/6.1.11. View

5.
Hartz D, Galloway G . Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis. Drug Alcohol Depend. 2001; 63(3):269-76. DOI: 10.1016/s0376-8716(00)00217-9. View